Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Urinary Bladder Neoplasms 2Glioma 2Oligodendroglioma 1Melanoma 1Lymphoma, Follicular 1Glioblastoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 4Erlotinib Hydrochloride 4Bevacizumab 4temsirolimus 3Radiotherapy 3Carboplatin 3etoposide phosphate 2Sirolimus 2Magnetic Resonance Spectroscopy 2Imatinib Mesylate 2Cetuximab 2Carmustine 2veliparib 1transforming growth factor(alpha)-Pseudomonas aeruginosa exotoxin (38) 1terameprocol 1sodium thiosulfate 1romidepsin 1picropodophyllin 1perifosine 1octadecyl-(N,N-dimethylpiperidino-4-yl)-phosphate 1mirdametinib 1irofulven 1efaproxiral 1carotuximab 1cabazitaxel 1acetyl-prolyl-histidyl-seryl-cysteinyl-asparaginamide 1Vorinostat 1Transurethral Resection of Bladder 1Surgical Procedures, Operative 1Spinal Puncture 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Oligodendroglioma × Transurethral Resection of Bladder × Clear all
NCT07468136 2026-04-13

Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

Mayo Clinic

Phase 1/2 Not yet recruiting
33 enrolled
CNSLymphoid

Astrocytoma, Glioblastoma, Glioma, Lymphoma, Follicular, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡